证券代码：002173 证券简称：创新医疗 公告编号：2025-024 创新医疗管理股份有限公司 关于持股 5%以上股东减持至 5%以下的权益变动提示性公告 持股 5%以上股东上海洸焕科技有限公司（曾用名：上海瑞鑫融资租赁有限 公司）及其一致行动人上海岩衡投资管理合伙企业（有限合伙）保证向本公司提 供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、本次权益变动后，上海洸焕科技有限公司（以下简称"上海洸焕"）持 有创新医疗管理股份有限公司（以下简称"公司"）股份22,064,122股，占公司 总股本的4.99998%，不再是公司持股5%以上股东。 2、本次上海洸焕及其一致行动人上海岩衡投资管理合伙企业（有限合伙） （以下简称"岩衡投资"）权益变动，系因公司回购注销业绩补偿股份及注销已 回购股份事项致其持股比例发生变动，及其因自身资金安排需要减持公司股份所 致。该权益变动不会导致公司控股股东、实际控制人发生变化，不会影响公司的 治理结构和持续经营。 公司于近日收到上海洸焕《简式权益变动报告书》等，获悉上海洸焕于2 ...

Group 1 - The core viewpoint of the news is that Innovation Medical's stock has shown a slight increase, but the company is facing significant challenges in its financial performance, with declining revenue and increasing losses [1] - As of April 29, Innovation Medical's closing price was 8.96 yuan, up 2.75%, with a latest price-to-book ratio of 2.24 and a total market capitalization of 3.954 billion yuan [1] - On April 29, the net inflow of main funds into Innovation Medical was 23.82 million yuan, but over the past five days, there was a total outflow of 22.19 million yuan [1] Group 2 - For the first quarter of 2025, Innovation Medical reported operating revenue of 193 million yuan, a year-on-year decrease of 3.98%, and a net loss of approximately 13.94 million yuan, a year-on-year increase in losses of 368.03%, with a gross profit margin of 8.96% [1] - The company has a TTM PE ratio of -37.69 and a static PE ratio of -42.08, indicating significant financial distress compared to the industry average PE ratios of 37.55 and 42.71 respectively [2] - The industry average market capitalization is 14.953 billion yuan, while Innovation Medical's market capitalization is significantly lower at 3.954 billion yuan [2]

证券代码：002173 证券简称：创新医疗 公告编号：2025-023 创新医疗管理股份有限公司 关于持股 5%以上股东权益变动触及 1%的提示性公告 股东上海洸焕科技有限公司保证向本公司提供的信息内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 创新医疗管理股份有限公司 创新医疗管理股份有限公司（以下简称"公司"）于2025年3月24日在《证 券时报》、《证券日报》、《上海证券报》、《中国证券报》和巨潮资讯网 （www.cninfo.com.cn）上披露了《关于持股5%以上股东、董事、高管减持股份 的预披露公告》（公告编号：2025-010），上海洸焕科技有限公司（以下简称"上 海洸焕"）计划以集中竞价交易、大宗交易方式减持本公司股份，减持数量不超 过13,238,487股，即不超过公司总股本的3%。 公司近日收到上海洸焕《股份减持计划实施触及变动1%的告知函》，自2025 年4月21日至2025年4月25日期间，上海洸焕权益变动触及公司总股本的1%。现将 具体情况公告如下： | 1．基本情况 | | | | | --- | ...

Core Viewpoint - The company, Innovation Medical, has released its first quarter report for 2025, which has not been audited, and emphasizes the accuracy and completeness of the financial information provided [3][6]. Financial Data Summary - The company confirms that there are no adjustments or restatements required for previous accounting data [3]. - There are no non-recurring profit and loss items applicable for the quarter [3]. - The company has not defined any non-recurring profit and loss items as recurring [3]. Shareholder Information - The report includes details about the total number of common shareholders and the top ten shareholders, but specific data is not provided in the document [5]. - The company has not engaged in any share lending activities related to the top ten shareholders [5]. Other Important Matters - The first quarter report has not undergone an audit, indicating that the financial statements are preliminary and subject to change [6].

Financial Performance - The company reported a basic earnings per share of -0.0300 yuan for Q1 2025, a decrease of 347.76% compared to -0.0067 yuan in Q1 2024 [1] - Net profit for Q1 2025 was -0.14 billion yuan, representing a significant decline of 366.67% from -0.03 billion yuan in Q1 2024 [1] - Operating revenue decreased by 3.98% to 1.93 billion yuan in Q1 2025, down from 2.01 billion yuan in Q1 2024 [1] - The return on equity was -0.79% in Q1 2025, a drop of 393.75% from -0.16% in Q1 2024 [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 15,020.82 million shares, accounting for 36.07% of the circulating shares, with a decrease of 302.26 million shares compared to the previous period [2] - The largest shareholder, Chen Xiaying, holds 7,761.70 million shares, representing 18.64% of the total share capital, with no change [3] - Shanghai Guanghuan Technology Co., Ltd. holds 3,372.02 million shares (8.10%), unchanged from the previous period [3] - Hangzhou Changjian Investment Partnership (Limited Partnership) decreased its holdings by 392.00 million shares to 1,814.42 million shares (4.36%) [3] Dividend Policy - The company has decided not to distribute dividends or transfer shares in this period [3]

Revenue and Profitability - The company's revenue for Q1 2025 was ¥193,334,481.58, a decrease of 3.98% compared to ¥201,344,535.99 in the same period last year[4] - The net profit attributable to shareholders was -¥13,937,418.26, representing a decline of 368.03% from -¥2,977,863.39 year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥14,970,488.85, a decrease of 452.67% compared to -¥2,708,735.09 in the previous year[4] - Basic and diluted earnings per share were both -¥0.03, down 347.76% from -¥0.0067 in the previous year[4] - Net profit for the current period was a loss of CNY 13,890,668.31, compared to a loss of CNY 2,979,559.99 in the previous period[15] - The net profit attributable to the parent company was -13,937,418.26, compared to -2,977,863.39 in the previous period, indicating a significant increase in losses[16] - The total comprehensive income attributable to the parent company was -13,937,418.26, compared to -2,977,863.39 in the previous period, reflecting a worsening financial position[16] - The basic and diluted earnings per share were both -0.03, compared to -0.0067 in the previous period, showing a decline in profitability[16] Cash Flow and Liquidity - The net cash flow from operating activities improved to ¥4,741,047.29, a significant increase of 126.84% from -¥17,663,752.00 in the same period last year[4] - Cash inflows from operating activities totaled 191,773,031.89, up from 182,904,706.98 in the previous period, indicating improved cash generation[17] - The net cash flow from operating activities was 4,741,047.29, a recovery from -17,663,752.00 in the previous period, suggesting operational improvements[18] - Cash inflows from investing activities were 55,025,416.74, down from 304,959,178.42 in the previous period, indicating reduced investment activity[18] - The net cash flow from investing activities was 21,058,502.54, a significant decrease from 288,142,403.29 in the previous period, reflecting a shift in investment strategy[18] - The net cash flow from financing activities was 486,724.90, down from 10,452,995.48 in the previous period, indicating a reduction in financing activities[18] - The ending cash and cash equivalents balance was 143,789,708.17, down from 529,951,281.78 in the previous period, showing a decrease in liquidity[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,164,041,606.40, a decrease of 1.81% from ¥2,203,947,708.41 at the end of the previous year[4] - Total operating costs increased to CNY 205,240,260.34, up 1.0% from CNY 202,244,492.52[15] - Total assets decreased to CNY 2,164,041,606.40 from CNY 2,203,947,708.41, reflecting a decline of 1.8%[14] - Total liabilities decreased to CNY 400,833,433.03 from CNY 426,848,866.73, a reduction of 6.1%[13] - Current assets totaled CNY 566,946,305.73, down 5.3% from CNY 598,852,540.99[12] - Non-current assets totaled CNY 1,597,095,300.67, a slight decrease from CNY 1,605,095,167.42[13] - The company's retained earnings showed a deficit of CNY 1,412,129,160.15, worsening from a deficit of CNY 1,398,191,741.89[13] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 68,155[9] Non-Recurring Items - The company reported a non-recurring gain of ¥1,033,070.59, primarily from fair value changes of financial assets and liabilities[5] - The decline in net profit was attributed to changes in payment methods for rehabilitation diseases and dynamic adjustments in medical insurance payment standards[7] Audit Status - The first quarter report was not audited, which may affect the reliability of the financial data presented[19]

Core Viewpoint - The company emphasizes the importance of innovation in the medical service industry, particularly in response to changes in medical insurance policies that affect profitability and operational efficiency [1][2]. Group 1: Company Operations - The company has experienced a decline in medical service gross margins due to adjustments in medical insurance settlement policies, despite an increase in outpatient and inpatient volumes [2]. - The company operates four hospitals: Jianhua Hospital, Kanghua Hospital, Futian Hospital, and Mingzhu Hospital, which are actively making adjustments to cope with market changes [2]. - The company is focusing on enhancing the quality and efficiency of its hospitals while investing in emerging medical technologies such as brain-computer interface (BCI) and AI medical models [2][4]. Group 2: AI Medical Model Development - The AI medical model developed by the company's affiliate, Quanzhen Medical, has demonstrated capabilities in providing diagnostic suggestions and generating medical records, significantly improving doctor efficiency and service quality [3]. - In 2024, Quanzhen Medical anticipates generating revenue of 4.4 million yuan from its AI medical model, with a target of 40 million yuan in 2025 [3]. - The company plans to expand its partnerships with hospitals, aiming to increase the number of collaborations from approximately 60 to 160 in the near future [3]. Group 3: Brain-Computer Interface (BCI) Project - The BCI project has developed a product line that includes systems for rehabilitation training and neuro-signal acquisition, with clinical trials already underway in several hospitals [4]. - The BCI products are expected to complete regulatory registration by mid-2026, with consumer products entering mass production and anticipated market launch in 2025 [4]. Group 4: Future Development Strategy - The company aims to enhance hospital operational capabilities and efficiency while actively exploring the commercialization of advanced medical technologies [5]. - The focus will be on capital operations that align with the company's strategic direction and investment value, leveraging technological advancements to improve the medical service industry [5].

Group 1: Company Overview and Performance - The company focuses on comprehensive medical services, primarily relying on local health insurance bureaus for revenue settlement [4] - Despite an increase in outpatient and inpatient volumes in 2024, the company's operating performance has declined due to adjustments in health insurance settlement policies, leading to reduced service charges and lower gross margins [4] - The company has invested in innovative projects such as brain-computer interfaces (BCI) and AI medical models to enhance traditional medical services [4] Group 2: AI Medical Model Development - The AI medical model currently collaborates with approximately 60 hospitals in 2024, with an expected increase of about 100 hospitals in 2025 [6] - Projected revenue for the AI medical model is estimated at 4.4 million in 2024 and aims for 40 million in 2025 [6] - The AI model has shown significant cost reduction and efficiency improvement in hospitals, particularly through features like in-clinic dictation and inpatient dictation [6] Group 3: BCI Product Development - The BCI product assists stroke patients in regaining control over their upper limb movements, enabling basic daily activities [7] - The BCI product can operate for approximately 6 hours on a single charge, with a replaceable battery [8] - The BCI product is undergoing multi-center clinical trials and is expected to complete registration for medical device classification by mid-2026 [8] Group 4: Market Impact and Financial Projections - The BCI product is anticipated to significantly reduce rehabilitation costs for patients, allowing families to save between 40,000 to 60,000 annually by replacing full-time caregivers with part-time help [10] - The pricing strategy for the BCI product is based on the value it provides to stroke patients, with specific pricing details to be announced upon launch [10]

证券代码：002173 证券简称：创新医疗 公告编号：2025-021 创新医疗管理股份有限公司 关于持股 5%以上股东权益变动触及 1%的提示性公告 股东上海洸焕科技有限公司保证向本公司提供的信息内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 | 股份种类（A 股、B 股等） | 减持股数（万股） 减持比例（%） | | | --- | --- | --- | | A 股 | 470 1.0651% | | | 合 计 | 470 1.0651% | | | 本次权益变动方式 | 通过证券交易所的集中交易 √ | | | | 通过证券交易所的大宗交易 √ | | | | 其他 □（请注明） | | | 3．本次变动前后，投资者及其一致行动人拥有上市公司权益的股份情况 | | | | 股份性质 | 本次变动前持有股份 本次变动后持有股份 | | | | 占总股本比 占总股本比 股数(万股) 股数(万股) | | | | 例(%) 例(%) | | | 合计持有股份 | 3,372.0222 7.6414% 2,902.0222 6.5763% | | | 其中：无限售条件股份 | 3,372.0 ...

■ ■ ■ 0 0 2173 ■ ■ ■ 5% ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ 2025 每4年13 ■ 2025 每4年18 ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ 1.0 © ■ ■ ■ ■ ■ ■ 1.06 5 1% ■ ...